Company: ARVN
Filing Date: 2025-04-28
Form Type: 8-K
Source: 0001655759-25-000069
Chunk: 1

Company: ARVINAS, INC.
Filing Date: 2025-04-28
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01 Other Events.

On April 28, 2025, the Company presented data from preclinical combination studies of ARV-393, the Company’s investigational PROTAC BCL6 degrader. The results from these preclinical studies were shared in a poster presentation at the AACR annual meeting in Chicago, Illinois.

Preclinical data demonstrated synergistic antitumor activity, including complete regressions, in combination with standard of care (“ SOC”) chemotherapy, SOC biologics, and investigational oral small molecule inhibitors (“ SMIs”) in high grade B-cell lymphoma (“ HGBCL”) and aggressive diffuse large B-cell lymphoma (“ DLBCL”) models. Key findings from the studies, as presented at the AACR annual meeting, are outlined below.

• ARV-393 in combination with SOC chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (“ R-CHOP”), induced significantly greater tumor growth inhibition compared with rituximab, CHOP, R-CHOP, or ARV-393 alone, with complete tumor regressions in all mice treated with the ARV-393 and R-CHOP combination.

• ARV-393 in combination with SOC biologics targeting CD20 (rituximab), CD19 (tafasitamab), or CD79b (polatuzumab vedotin) resulted in tumor regressions and demonstrated significantly stronger tumor growth inhibition compared with each agent alone.

• In preclinical models, ARV-393 increased CD20 expression, providing additional support for the exploration of combinations with CD20-targeted agents and in the context of low or loss of CD20 expression.

• ARV-393 in combination with investigational small molecule inhibitors targeting clinically validated oncogenic drivers of lymphoma, such as BTK (acalabrutinib), BCL2 (venetoclax), or EZH2 (tazemetostat), resulted in superior tumor growth inhibition compared with each agent alone, with tumor regressions in all mice treated with the combinations.

Item 9.01 Financial Statements and Exhibits.